Imagine sitting in a memory clinic in Manchester or Munich, finally hearing the words you have dreaded early-stage Alzheimer's disease only to be told in the same breath that, yes, a drug now exists that could slow what is happening to your brain, but no, you cannot have it. For thousands of families across the UK and the European Union, this is no longer a hypothetical. After decades in which dementia patients were offered little beyond symptom management and supportive care, two genuinely disease-modifying treatments have arrived: lecanemab, sold as Leqembi, and donanemab, sold as Kisunla. Both are monoclonal antibodies that target and clear the sticky amyloid plaques believed to drive Alzheimer's, and both have produced the first credible evidence that the disease's trajectory can be bent rather than merely cushioned. Yet the gap between scientific possibility and real-world access has rarely been so stark, and nowhere is that gap more visible than in the deepening divide between approval in Brussels and denial at home in Britain.
To understand the controversy, it helps to be precise about what these drugs actually do and for whom. Lecanemab and donanemab are not cures, and they are not for everyone with memory problems. They are licensed only for people in the earliest stages of the Alzheimer's pathway those with mild cognitive impairment or mild dementia who have confirmed amyloid build-up in the brain. In the pivotal Clarity AD trial, lecanemab slowed cognitive and functional decline by roughly 27% over 18 months compared with placebo, while donanemab's TRAILBLAZER-ALZ 2 study reported broadly comparable slowing, with the strongest effect in patients who had lower levels of the tau protein. In practical terms, that 27% does not reverse decline or restore lost memories; it buys time, potentially several months of preserved independence, daily function and recognition of loved ones. Whether that is modest or meaningful depends entirely on where you are standing a statistician may call it marginal, while a family watching a parent fade may call it priceless. The benefits, however, come tethered to real risks. Both drugs can cause ARIA, amyloid-related imaging abnormalities, a clinical term for brain swelling and micro-bleeds that show up on MRI scans. ARIA is often asymptomatic but can occasionally be serious or even fatal, and the risk is markedly higher in people who carry two copies of the APOE4 gene, which is precisely why regulators have grown cautious about who should be treated and how closely they must be watched.
This brings us to the regulatory divide that has left British patients feeling uniquely abandoned. In the UK, the system split in two. The Medicines and Healthcare products Regulatory Agency, the MHRA, judged both lecanemab and donanemab to be safe and effective enough to be licensed a clear scientific endorsement that these drugs work. But licensing a drug and paying for it on the NHS are entirely separate decisions, and the second belongs to the National Institute for Health and Care Excellence, NICE. After repeated appraisals, NICE concluded that the Alzheimer's drug benefits, while real, simply did not justify the cost to a stretched health service once the price of the medicine, the infusions, the diagnostic scans and the intensive MRI monitoring were all added together. The result is one of the most jarring contradictions in modern British medicine: a treatment deemed good enough to be legally sold in the UK, yet not good enough value to be funded by the NHS. The NICE rejection of these Alzheimer's drugs has effectively created a two-tier reality, in which the only route to lecanemab on the NHS is closed, and access depends on the ability to pay privately. Across the Channel, the European Medicines Agency took its own winding path. The EMA initially declined lecanemab over safety concerns, then reversed its position and granted a restricted approval, limiting the drug to a narrower, lower-risk group specifically excluding those with two copies of the APOE4 gene who face the highest ARIA danger. That EMA Alzheimer's approval did not, however, guarantee smooth access. Each EU member state still decides on reimbursement and rollout, so a patient in Germany, where private and insured pathways are more developed, may find treatment within reach, while a patient in a smaller or more cash-constrained health system faces a postcode lottery of their own. Early dementia treatment in Europe is therefore not a single story but a patchwork, with the UK now sitting awkwardly outside even that uneven map.
For families weighing their next move, the practical questions matter more than the politics. The first and most decisive step is securing an early and accurate diagnosis, because these amyloid plaque drugs only work in the early window and only in people with confirmed amyloid pathology. That confirmation requires either a PET scan or a lumbar puncture to test cerebrospinal fluid, and here lies a hidden bottleneck: most NHS memory clinics, and many of their EU counterparts, were never built to deliver this kind of rapid biomarker testing at scale, let alone the ongoing MRI surveillance that ARIA monitoring demands. A diagnosis of "probable Alzheimer's" from a standard memory assessment is no longer sufficient; eligibility now hinges on hard biological evidence. Those who do qualify and choose to go private should understand the true cost before committing. The headline drug price is only the beginning once you factor in the diagnostic work-up, the fortnightly or monthly infusions, the repeated MRI scans and specialist oversight, private UK clinics are quoting figures in the region of £60,000 to £80,000 a year. The Leqembi cost in the UK and the Kisunla price are not one-off expenses but an open-ended annual commitment, and that arithmetic alone places private Alzheimer's treatment in the UK beyond the reach of most. Anyone considering it should press their clinic with direct questions: Am I genuinely eligible based on biomarker testing and APOE4 status? What is the full all-in annual cost, including monitoring? How will ARIA be detected and managed if it occurs? And what happens, clinically and financially, if I have to stop?
Looking ahead, the real battle is less about these two specific molecules and more about the infrastructure and philosophy underpinning dementia care across both the UK and EU. Around 982,000 people are currently living with dementia in the UK, a number projected to climb to 1.4 million by 2040, with Alzheimer's the most common cause a scale that makes today's access decisions a rehearsal for far larger pressures to come. The donanemab and lecanemab debate has exposed an uncomfortable truth: even if every cost objection were resolved tomorrow, the health systems simply lack the diagnostic and monitoring capacity to treat the eligible population. My expectation is that the next few years will see this divide narrow not through a sudden NICE reversal but through three converging forces cheaper and simpler blood-based diagnostic tests that bypass the PET and lumbar puncture bottleneck, the arrival of competing and eventually lower-priced amyloid therapies that shift the cost-effectiveness maths, and growing political pressure as the contrast between EMA Alzheimer's approval and UK denial becomes harder to defend. Families should not wait passively for that future. Seeking an early diagnosis now, understanding your eligibility, joining patient registries and research trials, and pressing both clinicians and policymakers on fair access are the most powerful steps available today. The science has, at last, delivered a reason for hope in early-stage Alzheimer's; the unfinished task is ensuring that hope is not reserved for those who can afford to cross a border or write a cheque.
Comments
Post a Comment